Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Eliem Therapeutics, Inc. (ELYM : NSDQ)
 
 • Company Description   
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.

Number of Employees: 25

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.64 Daily Weekly Monthly
20 Day Moving Average: 41,223 shares
Shares Outstanding: 26.55 (millions)
Market Capitalization: $282.47 (millions)
Beta:
52 Week High: $29.69
52 Week Low: $10.52
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -40.29% -38.43%
12 Week -58.47% -58.88%
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
23515 NE NOVELTY HILL ROAD SUITE B221 #125
-
REDMOND,WA 98053
USA
ph: 425-276-2300
fax: -
investorrelations@eliemtx.com http://www.eliemtx.com
 
 • General Corporate Information   
Officers
Robert Azelby - Chief Executive Officer
Andrew Levin - Chairman
Erin M. Lavelle - Chief Operating Officer and Chief Financial Office
James B. Bucher - Executive Vice President
Adam Rosenberg - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 28658R106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 02/14/22
Share - Related Items
Shares Outstanding: 26.55
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $282.47 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-7.55 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/14/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.60
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 77.49%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/21 - -
06/30/21 - -
03/31/21 - -
ROA
09/30/21 - -
06/30/21 - -
03/31/21 - -
Current Ratio
09/30/21 - 28.38
06/30/21 - 18.34
03/31/21 - -
Quick Ratio
09/30/21 - 28.38
06/30/21 - 18.34
03/31/21 - -
Operating Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Net Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - 6.65
06/30/21 - -
03/31/21 - -
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.00
06/30/21 - -
03/31/21 - -
Debt-to-Capital
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - -
 

Powered by Zacks Investment Research ©